Improved technology now allows students better access and results, says Coursera co-founder Daphne Koller.
The roadmap for Christmas 2014 will need to look decidedly different for retailers to achieve 4 percent-plus sales growth.
In order to attract business from the country's fastest-growing demographic, advisors need to speak to millennials in their own language.
Robin Hayes has heard investors' calls for JetBlue to increase its ancillary revenues, but he needs to be careful not to damage JetBlue's image.
Another strange wrinkle in oilman Harold Hamm's divorce case has emerged.
Colorado and Oregon ballot measures to label food products that have GMOs were defeated, but proponents vow to fight on.
Sen. John Barrasso, chairman of the Senate Republican Policy Committee, tells CNBC the president fails to realize what happened in the midterms.
The group of the world’s biggest global oil exporters has cut its forecasts for the price growth and global demand for oil.
Even guys who had to bear the weight of the world on their shoulders can laugh a little, too.
This is a link to Qualcomm's ticker symbol.
McDonald's let franchisees choose whether to bring back the McRib this year. Many fans won't be lovin' the outcome.
Whole Foods' strong quarterly results shows the organic grocer is turning things around, says CNBC's Jim Cramer.
We might have been talking about it for years, but it's far from obvious that the so-called Internet of Things has arrived.
U.S. equities are likely to rise over the next year, but markets need time to repair after last month's selloff and could face tests, said Bob Doll.
Broadcast TV actually fares better than basic cable now, at least in terms of ratings and ad revenue, says CBS CEO Les Moonves.
One trader is placing a big speculative bet on energy stocks—and he's found a very clever way to do it.
Recent bankruptcy proceedings in Detroit and elsewhere should raise a giant warning flag for investors, says UBS's head of muni investing.
Fewer investors are going all-in with their retirement savings.
The number of Americans filing new claims for unemployment benefits fell more than expected, while U.S. productivity came in better than forecast.
The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.